Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of VcR-CAP versus R-CHOP in newly diagnosed mantle cell lymphoma not eligible for transplant
2007-005669-37Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2008
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in mantle cell lymphoma (MCL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Jan 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2007-005669-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005669-37.